|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith RA, Manassaram-Baptiste D, Brooks D,
Doroshenk M, Fedewa S, Saslow D, Brawley OW and Wender R: Cancer
screening in the United States, 2015: A review of current American
cancer society guidelines and current issues in cancer screening.
CA Cancer J Clin. 65:30–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:2783–2795. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cha YJ and Koo JS: Next-generation
sequencing in thyroid cancer. J Transl Med. 14:3222016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hunt J: Understanding the genotype of
follicular thyroid tumors. Endocr Pathol. 16:311–321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang QX, Chen ED, Cai YF, Li Q, Jin YX,
Jin WX, Wang YH, Zheng ZC, Xue L, Wang OC and Zhang XH: A panel of
four genes accurately differentiates benign from malignant thyroid
nodules. J Exp Clin Cancer Res. 35:1692016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watanabe R, Hayashi Y, Sassa M, Kikumori
T, Imai T, Kiuchi T and Murata Y: Possible involvement of BRAFV600E
in altered gene expression in papillary thyroid cancer. Endocr J.
56:407–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nikiforova MN and Nikiforov YE: Molecular
diagnostics and predictors in thyroid cancer. Thyroid.
19:1351–1361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang KT and Lee CH: BRAF mutation in
papillary thyroid carcinoma: Pathogenic role and clinical
implications. J Chin Med Assoc. 73:113–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang Y, Prasad M, Lemon WJ, Hampel H,
Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, et
al: Gene expression in papillary thyroid carcinoma reveals highly
consistent profiles. Proc Natl Acad Sci USA. 98:15044–15049. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prasad ML, Pellegata NS, Kloos RT,
Barbacioru C, Huang Y and de la Chapelle A: CITED1 protein
expression suggests Papillary Thyroid Carcinoma in high throughput
tissue microarray-based study. Thyroid. 14:169–175. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shioda T, Fenner MH and Isselbacher KJ:
MSG1, a novel melanocyte-specific gene, encodes a nuclear protein
and is associated with pigmentation. Proc Natl Acad Sci USA.
93:12298–12303. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yahata T, Shao W, Endoh H, Hur J, Coser
KR, Sun H, Ueda Y, Kato S, Isselbacher KJ, Brown M and Shioda T:
Selective coactivation of estrogen-dependent transcription by
CITED1 CBP/p300-binding protein. Genes Dev. 15:2598–2612. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shioda T, Fenner MH and Isselbacher KJ:
MSG1 and its related protein MRG1 share a transcription activating
domain. Gene. 204:235–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prasad ML, Pellegata NS, Huang Y, Nagaraja
HN, de la Chapelle A and Kloos RT: Galectin-3, fibronectin-1,
CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful
for the differential diagnosis of thyroid tumors. Mod Pathol.
18:48–57. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li H, Ahmed NU, Fenner MH, Ueda M,
Isselbacher KJ and Shioda T: Regulation of expression of MSG1
melanocyte-specific nuclear protein in human melanocytes and
melanoma cells. Exp Cell Res. 242:478–486. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sedghizadeh PP, Williams JD, Allen CM and
Prasad ML: MSG-1 expression in benign and malignant melanocytic
lesions of cutaneous and mucosal epithelium. Med Sci Monit.
11:BR189–BR194. 2005.PubMed/NCBI
|
|
18
|
Lovvorn HN III, Boyle S, Shi G, Shyr Y,
Wills ML, Perantoni AO and de Caestecker M: Wilms' tumorigenesis is
altered by misexpression of the transcriptional co-activator,
CITED1. J Pediatr Surg. 42:474–481. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schweppe RE, Klopper JP, Korch C,
Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland
JA, Smallridge RC and Haugen BR: Deoxyribonucleic acid profiling
analysis of 40 human thyroid cancer cell lines reveals
cross-contamination resulting in cell line redundancy and
misidentification. J Clin Endocrinol Metab. 93:4331–4341. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuo SF, Lin SF, Chao TC, Hsueh C, Lin KJ
and Lin JD: Prognosis of multifocal papillary thyroid carcinoma.
Int J Endocrinol. 2013:8093822013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sancho JJ, Lennard TW, Paunovic I,
Triponez F and Sitges-Serra A: Prophylactic central neck disection
in papillary thyroid cancer: A consensus report of the European
society of endocrine surgeons (ESES). Langenbecks Arch Surg.
399:155–163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pereira JA, Jimeno J, Miquel J, Iglesias
M, Munné A, Sancho JJ and Sitges-Serra A: Nodal yield, morbidity,
and recurrence after central neck dissection for papillary thyroid
carcinoma. Surgery. 138:1095–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Machens A, Hinze R, Thomusch O and Dralle
H: Pattern of nodal metastasis for primary and reoperative thyroid
cancer. World J Surg. 26:22–28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zaydfudim V, Feurer ID, Griffin MR and
Phay JE: The impact of lymph node involvement on survival in
patients with papillary and follicular thyroid carcinoma. Surgery.
144:1070–1078. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leboulleux S, Rubino C, Baudin E, Caillou
B, Hartl DM, Bidart JM, Travagli JP and Schlumberger M: Prognostic
factors for persistent or recurrent disease of papillary thyroid
carcinoma with neck lymph node metastases and/or tumor extension
beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol
Metab. 90:5723–5729. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cancer Genome Atlas Research Network:
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McBryan J, Howlin J, Kenny PA, Shioda T
and Martin F: ERalpha-CITED1 co-regulated genes expressed during
pubertal mammary gland development: Implications for breast cancer
prognosis. Oncogene. 26:6406–6419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murphy AJ, de Caestecker C, Pierce J,
Boyle SC, Ayers GD, Zhao Z, Libes JM, Correa H, Walter T, Huppert
SS, et al: CITED1 expression in liver development and
hepatoblastoma. Neoplasia. 14:1153–1163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sassa M, Hayashi Y, Watanabe R, Kikumori
T, Imai T, Kurebayashi J, Kiuchi T and Murata Y: Aberrant promoter
methylation in overexpression of CITED1 in papillary thyroid
cancer. Thyroid. 21:511–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nasu T, Oku Y, Takifuji K, Hotta T,
Yokoyama S, Matsuda K, Tamura K, Ieda J, Yamamoto N, Takemura S, et
al: Predicting lymph node metastasis in early colorectal cancer
using the CITED1 expression. J Surg Res. 185:136–142. 2013.
View Article : Google Scholar : PubMed/NCBI
|
